Novozymes A/S
NVZMFOTCBasic Materials● Active
$56.36
$-1.42(-2.45%)
Market Cap$26.3B
P/E Ratio—
52W High$75.97
52W Low$52.1
Novozymes A/S (NVZMF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVZMF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.66
Est. $0.81 · -17.9%
Revenue
$1.29B
Est. $1.30B · -0.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
NVZMF reports quarterly as a OTC-listed Chemicals - Specialty company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 20, 2026 | $0.76 | — | — | — | $1.28B | — |
| ▼ Q2 FY2026 | May 5, 2026 | $0.81 | $0.66 | -17.9% | $1.29B | $1.30B | -0.9% |
| ▼ Q1 FY2026 | Feb 25, 2026 | $0.79 | $0.53 | -33.1% | $1.17B | $1.20B | -2.8% |
| ▼ Q3 FY2025 | Aug 21, 2025 | $0.68 | $0.34 | -49.7% | $1.20B | $1.20B | -0.4% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.43 | $0.06 | -85.2% | $0.16B | $1.17B | -86.4% |
| ▼ Q1 FY2025 | Feb 26, 2025 | $1.08 | $0.07 | -93.2% | $0.28B | $1.13B | -75.6% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.57 | $0.48 | -16.5% | $1.10B | $1.10B | -0.5% |
| ▼ Q3 FY2024 | Aug 27, 2024 | $0.70 | $0.12 | -82.4% | $0.98B | $0.16B | +514.8% |
Q3 FY2026
Aug 20, 2026
EPS Actual
—
EPS Est.
$0.76
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
$0.66
EPS Est.
$0.81
EPS Surpr.
-17.9%
Revenue
$1.29B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
$0.53
EPS Est.
$0.79
EPS Surpr.
-33.1%
Revenue
$1.17B
Q3 FY2025
Aug 21, 2025Miss
EPS Actual
$0.34
EPS Est.
$0.68
EPS Surpr.
-49.7%
Revenue
$1.20B
Q2 FY2025
May 8, 2025Miss
EPS Actual
$0.06
EPS Est.
$0.43
EPS Surpr.
-85.2%
Revenue
$0.16B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
$0.07
EPS Est.
$1.08
EPS Surpr.
-93.2%
Revenue
$0.28B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.48
EPS Est.
$0.57
EPS Surpr.
-16.5%
Revenue
$1.10B
Q3 FY2024
Aug 27, 2024Miss
EPS Actual
$0.12
EPS Est.
$0.70
EPS Surpr.
-82.4%
Revenue
$0.98B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $10.08 | $10.13 | $10.18 | 1 |
| Q2 FY2030 | $6.16 | $6.19 | $6.23 | 1 |
| Q1 FY2030 | $6.35 | $6.38 | $6.41 | 1 |
| Q4 FY2029 | $4.13 | $4.15 | $4.17 | 1 |
| Q3 FY2029 | $7.00 | $7.04 | $7.07 | 1 |
| Q2 FY2029 | $4.52 | $4.54 | $4.57 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $16.8B | $16.9B | $16.9B | 1 |
| Q2 FY2030 | $16.2B | $16.3B | $16.4B | 1 |
| Q1 FY2030 | $15.4B | $15.5B | $15.5B | 1 |
| Q4 FY2029 | $15.3B | $15.4B | $15.4B | 1 |
| Q3 FY2029 | $13.5B | $13.6B | $13.6B | 1 |
| Q2 FY2029 | $13.5B | $13.5B | $13.6B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -17.9% | $62.49 | $63.35 | +1.38% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -33.1% | $60.97 | $57.44 | -5.79% |
| ▼ Q3 FY2025 | Aug 21, 2025 | -49.7% | $66.00 | $61.49 | -6.83% |
| ▼ Q2 FY2025 | May 8, 2025 | -85.2% | $62.15 | $62.15 | +0.00% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -93.2% | $57.26 | $60.13 | +5.01% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -16.5% | $58.97 | $59.74 | +1.31% |
| ▼ Q3 FY2024 | Aug 27, 2024 | -82.4% | $68.45 | $69.87 | +2.07% |
| ▲ Q2 FY2024 | May 3, 2024 | +85.7% | $54.00 | $60.84 | +12.67% |
Q2 FY2026+1.38%
Report Date
May 5, 2026
EPS Beat/Miss
-17.9%
Price Before
$62.49
Price After
$63.35
Q1 FY2026-5.79%
Report Date
Feb 25, 2026
EPS Beat/Miss
-33.1%
Price Before
$60.97
Price After
$57.44
Q3 FY2025-6.83%
Report Date
Aug 21, 2025
EPS Beat/Miss
-49.7%
Price Before
$66.00
Price After
$61.49
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
-85.2%
Price Before
$62.15
Price After
$62.15
Q1 FY2025+5.01%
Report Date
Feb 26, 2025
EPS Beat/Miss
-93.2%
Price Before
$57.26
Price After
$60.13
Q4 FY2024+1.31%
Report Date
Nov 7, 2024
EPS Beat/Miss
-16.5%
Price Before
$58.97
Price After
$59.74
Q3 FY2024+2.07%
Report Date
Aug 27, 2024
EPS Beat/Miss
-82.4%
Price Before
$68.45
Price After
$69.87
Q2 FY2024+12.67%
Report Date
May 3, 2024
EPS Beat/Miss
+85.7%
Price Before
$54.00
Price After
$60.84
Avg Beat Reaction+12.67%
Avg Miss Reaction-0.41%
Beat Rate1 / 8 quarters
Largest Move+12.67% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVZMF ends December
Novozymes A/S (NVZMF) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.66 — missing the analyst consensus of $0.81 by -17.9%. The next NVZMF earnings date is expected around September 1, 2026.
Each quarter, investors track NVZMF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVZMF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVZMF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVZMF earnings · 5 questionsNovozymes A/S's next earnings report is expected around September 1, 2026. NVZMF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVZMF historically reports after market close (AMC).
NVZMF earnings datewhen is NVZMF earningsNVZMF next earnings datewhen does NVZMF report earningsNVZMF earnings calendar
▸ Source: FMP · Novozymes A/S SEC filings · US GAAP · Novozymes A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026